MarketVIEW Endemic Vaccines  ·  September 2024 edition

Dengue Endemic Vaccines
Commercial Forecast

Dengue's vaccine market is going through the sharpest realignment in its short history. Sanofi is fully exiting Dengvaxia, Takeda's Qdenga (TAK-003) is scaling into dozens of new markets including India, and Instituto Butantan's single-dose Butantan-DV has just entered national rollout in Brazil - all against a backdrop of the highest global dengue burden ever recorded. This report forecasts that opportunity by competitor across 55 endemic markets to 2036, drawing on our long-standing, independent expertise in arboviral disease intelligence. Travel-related dengue vaccination demand is modelled separately in our Travel Vaccines Segment Report (VAMV090).

Record 2024 Global Burden Dengvaxia Exit (Sanofi) Qdenga Scale-Up (Takeda) Butantan-DV Entry (Brazil)
Product catalogue
VAMV025
September 2024 edition

Format
>375-slide deck + 250-tab Excel model
Coverage
55 endemic markets to 2036
Vaccines assessed
Dengvaxia, Qdenga, Butantan-DV
Markets
Public & private, endemic only
Approach
LO / BASE / HI scenarios
Availability
Direct licence, subject to refresh scope
14.4m
Dengue cases reported to WHO
in 2024 - the highest ever recorded
>100
Countries with endemic dengue
transmission, all six WHO regions
259%
Qdenga revenue growth,
Q4 FY2024/25 vs prior year
79.6%
Butantan-DV 2-year efficacy,
irrespective of baseline serostatus
Disease background

Why dengue remains the hardest vaccine problem in arbovirology

Dengue's biology is precisely what makes it commercially and clinically difficult: four distinct serotypes, a genuine risk that imperfect immunity makes disease worse rather than better, and a vector range that is still expanding. Understanding this is central to understanding why three very different vaccine strategies are now competing for the same market.

WHO & peer-reviewed 2024-26 data

Pathogen overview - Dengue virus (family Flaviviridae)

Dengue virus (DENV) is a single-stranded, positive-sense RNA virus of the genus Orthoflavivirus, family Flaviviridae, transmitted principally by the Aedes aegypti and, to a lesser extent, Aedes albopictus mosquitoes. Uniquely among the major arboviral vaccine targets, dengue exists as four antigenically distinct serotypes (DENV-1 to DENV-4), each capable of causing the full clinical spectrum from asymptomatic infection through classic dengue fever to severe dengue (dengue haemorrhagic fever and dengue shock syndrome).

The central scientific challenge is antibody-dependent enhancement (ADE). Infection with one serotype generally confers durable immunity against that serotype but only short-lived cross-protection against the others. On secondary infection with a different serotype, non-neutralising cross-reactive antibodies from the first infection can facilitate viral entry into Fc-receptor-bearing cells, materially raising the risk of severe disease rather than protecting against it. This is precisely why Sanofi's first-generation Dengvaxia was ultimately restricted to individuals with confirmed prior dengue exposure only, and why every serious competitor programme since has been built around demonstrating balanced, durable protection across all four serotypes regardless of baseline serostatus.

The disease burden is also still growing. WHO estimates around 390 million dengue infections occur worldwide each year, of which roughly 96 million manifest clinically, with the true burden considered substantially under-reported across much of the endemic world. Climate change, unplanned urbanisation and the northward and southward creep of Aedes mosquito populations - now established in parts of southern Europe and the continental United States - continue to expand the geographic footprint of transmission beyond its traditional tropical and subtropical range.

2024 was the worst year for dengue ever documented. WHO received reports of 14,434,584 cases globally, including 7,718,585 laboratory-confirmed cases, 52,738 classified as severe, and 11,201 deaths, across more than 100 countries in all six WHO regions. The Region of the Americas accounted for over 90% of the global total, with Brazil alone reporting more than 10 million cases and 6,321 deaths; Argentina, Mexico, Colombia, Paraguay, Peru, Guatemala and Honduras each recorded well over 150,000 cases. By epidemiological week 36 of 2025, suspected cases in the Americas had fallen by around 68% against the same period in 2024 - a reminder that dengue transmission is cyclical as well as structurally rising, and that scenario-based forecasting, not a single trend line, is what a serious commercial model requires.

2024 Highest global dengue burden ever recorded  |  >100 countries affected  |  Americas >90% of global cases
Product & competitor landscape

One market, three vaccines moving in three different directions

Within a single eighteen-month window the field's original entrant is exiting, its main current beneficiary is scaling rapidly into new geographies, and a genuinely new single-dose competitor has entered national rollout. VacZine Analytics tracks all three, plus the wider licensee network building on the same underlying science.

  • SanofiGlobal exit, Q3 2026
    Dengvaxia (CYD-TDV) Restricted label, seropositive only
    The first licensed dengue vaccine, but commercially constrained from the outset by its ADE-driven restriction to individuals with confirmed prior dengue infection, which in turn required costly pre-vaccination screening in most markets. The European Commission withdrew Dengvaxia's EU marketing authorisation in October 2025 at Sanofi's own request, and Sanofi has confirmed it will discontinue manufacturing and global marketing of the product in the third quarter of 2026, citing low demand. Existing stock carries an expiry of August 2026, after which no new patients can begin the vaccination series - a definitive end to the product that opened this market.
  • TakedaReport focus - scaling fast
    Qdenga (TAK-003) ~42 countries approved
    A tetravalent, live-attenuated vaccine that, unlike Dengvaxia, does not require pre-vaccination serostatus testing and is approved for use regardless of prior dengue exposure. Qdenga is now authorised in the EU, UK, Brazil, Argentina, Indonesia, Thailand, Malaysia, Vietnam and, as of July 2026, India - its first-ever approved dengue vaccine, cleared by the DCGI for ages 4 to 60. Quarterly revenue grew 259% year-on-year in Q4 FY2024/25 to JPY 35.6bn (approximately $247.7m). Takeda withdrew its US FDA application citing a data-collection disagreement, leaving the US without an active approval pathway following Dengvaxia's exit. Manufacturing is scaling via a partnership with Biological E in India (up to 50 million doses per year), part of a stated ambition to reach 100 million doses of annual capacity. On 18 September 2026, Takeda signed an exclusive agreement with Dr Reddy's Laboratories to promote and distribute Qdenga across India's private market (paediatric and adult), with Takeda retaining public-sector commercialisation rights; launch is anticipated in H1 2027, subject to completion of local regulatory processes. On 4 November 2026, PAHO's Strategic Advisory Group on Vaccine-Preventable Diseases published formal region-wide recommendations on Qdenga's use across the Americas, backing vaccination for ages 6 to 59 in areas with high dengue burden and sustained transmission (recent seroprevalence above 60% among 9-year-olds, or a mean age of peak dengue hospitalisations under 16 in the latest epidemic year), advising against co-administration with other vaccines - including yellow fever, hepatitis A and HPV - during national programme introduction, and calling for strengthened ESAVI surveillance, including tracking of inadvertent vaccination in pregnancy.
  • Instituto ButantanRollout paused, June 2026
    Butantan-DV World's first single-dose dengue vaccine
    Developed from the US NIH's live-attenuated TV003/TV005 tetravalent construct, licensed to Brazil's Instituto Butantan for local development and manufacture. Two-year vaccine efficacy of 79.6% against symptomatic, virologically confirmed dengue has been demonstrated irrespective of baseline serostatus - directly addressing the ADE concern that constrained Dengvaxia. Brazil's Anvisa approved Butantan-DV in November 2025 for ages 12 to 59, and the Ministry of Health began free rollout through the SUS public health system from 9 February 2026, starting with roughly 1.1 million primary healthcare workers and targeting more than 30 million doses by mid-2026. Butantan has partnered with China's WuXi Vaccines to manufacture 60 million doses over two years. On 8 June 2026, however, the Ministry of Health temporarily discontinued the Butantan-DV vaccination strategy as a precautionary measure, after 42 individuals (around 0.008% of roughly 501,000 people vaccinated) reported unusual adverse events - including severe abdominal pain, persistent vomiting and bleeding, with three serious cases and two deaths - though causality with the vaccine has not been established. Anvisa has convened an independent expert panel alongside the Ministry and Instituto Butantan to widen the epidemiological investigation, with no confirmed timeline yet for resuming the programme; Qdenga and other dengue vaccines are unaffected by the pause.
  • Wider TV003/TV005 networkLicensees
    Panacea Biotec (India), VaBiotech (Vietnam) and other licensees
    The same NIH-originated construct underlying Butantan-DV has been sublicensed to several other developing-country manufacturers pursuing their own regulatory pathways, a structurally important detail for any long-run assessment of global dengue vaccine supply and pricing. Notably, no major mRNA developer has yet advanced a dengue candidate into clinical development - an absence this report flags explicitly as a pipeline gap rather than a settled outcome.
Report focus
3-way shift

This three-way transition is the defining commercial story in dengue, and the reason this remains a genuinely comprehensive report. An exit, a scale-up and a new entrant are unfolding simultaneously, each with different serostatus requirements, different price tiers and different public/private market structures. VacZine Analytics models the commercial consequences of each - including the open question of who, if anyone, fills the US market gap left by Dengvaxia's exit and Qdenga's stalled FDA pathway - across 55 endemic markets. Travel-related dengue vaccination demand sits outside this report's scope and is modelled separately in VAMV090.

Scope of analysis

Six analytical layers - one wide-geography commercial picture

The MarketVIEW dengue analysis spans disease burden, the ADE-driven immunology that shapes every product's label, the three-way competitive landscape, and scenario-based value and volume forecasting across 55 endemic markets to 2036. Travel-related dengue vaccination demand is not forecast in this report - see our companion Travel Vaccines Segment Report (VAMV090) for that segment.

Global epidemiology & burden model

Record 2024 case data, serotype circulation patterns and regional breakdowns across the Americas, South-East Asia and Western Pacific.

Competitor & pipeline review

Dengvaxia's exit, Qdenga's scale-up and Butantan-DV's entry assessed head-to-head, alongside the wider TV003/TV005 licensee network.

Value & volume forecasts to 2036

LO, BASE and HI scenarios across 55 endemic markets, public and private sector, in $m value and mio-dose volume terms.

Pricing & market access

Tiered pricing across private and public endemic channels, plus GAVI and public-programme economics for Butantan-DV.

ADE & immunology risk assessment

Antibody-dependent enhancement explained and applied commercially: serostatus screening requirements and their effect on uptake and cost per dose.

Country & intra-state roll-out modelling

Mass campaign, routine-inclusion and approval-timeline scenarios by market, with intra-country regional roll-out analysis for Brazil and India.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the vaccine-level and market-structure framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.

Vaccine / developerSerostatus requirementStatus (2026)Market typeForecast scenario
Dengvaxia (Sanofi)Seropositive onlyGlobal exit, Q3 2026Public & private, legacyModelled
Qdenga (Takeda)None requiredScaling, ~42 marketsPublic & private, endemicModelled
Butantan-DV (Instituto Butantan)None requiredBrazil national rolloutPublic (SUS), single doseModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAllAllAll profiles$███m
Full model in the licensed workbook
55 endemic markets · LO / BASE / HI scenarios · value & volume · pricing detail
Request the full model →
Deliverables

What you receive

This MarketVIEW product consists of a detailed executive presentation (>375 slides) and a comprehensive MS-Excel forecast model (250 worksheets) which forecast the potential commercial value of dengue endemic vaccine(s) by competitor across 55 endemic markets to 2036.

  • Executive presentation (>375 slides) - disease background, epidemiology, the ADE mechanism, vaccine profiles and full commercial assessment with supporting narrative and references
  • Interactive MS-Excel forecast model (250 worksheets) - value ($m) and volume (mio doses) predictions, public and private sector, in adjustable age segments (e.g. >4 yrs, >19 yrs)
  • LO, BASE and HI forecast scenarios - including potential demand from selected country mass campaigns, routine inclusion and expected approvals from 2022 onwards
  • Intra-state / region roll-out analysis - sub-national rollout modelling for Brazil and India, the two markets with the most advanced state-by-state or region-by-region dengue vaccine deployment to date
  • Three-way competitor deep-dive - Dengvaxia's exit terms and timeline, Qdenga's country-by-country scale-up, and Butantan-DV's Brazilian rollout and manufacturing partnerships
  • Wider pipeline intelligence - the TV003/TV005 licensee network and an explicit assessment of the mRNA pipeline gap in dengue
  • Updated epidemiology module - record 2024 global case, death and severity data, regional breakdowns and the 2025 Americas decline in context
  • New case studies (2024) - added to guide forecast uptake projections

Not included: travel-related dengue vaccination demand, which is forecast separately in our Travel Vaccines Segment Report (VAMV090).

Target audience

Built for organisations weighing the dengue opportunity

Most valuable to teams evaluating the dengue market against their own pipeline, BD ambitions or investment thesis - particularly in the context of the Dengvaxia exit, Qdenga's expansion and Butantan-DV's entry.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for dengue candidates at any stage.

Corporate strategy & BD

Validate market size and structure as Dengvaxia exits and Qdenga and Butantan-DV compete for the space it vacates.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on dengue vaccine assets.

Public health & procurement

Endemic-programme feasibility and procurement economics for GAVI-eligible and middle-income country rollouts.

Market access & pricing teams

Endemic public/private pricing tiers, GAVI economics and country-level access planning across all 55 modelled markets.

Researchers & academia

Comprehensive epidemiology, immunology and vaccine-landscape context for grant and translational planning.

About this analysis · VAMV025

This is a genuinely comprehensive report, with a wide geographic focus across 55 endemic markets that reflects VacZine Analytics' long-standing, independent expertise in arboviral disease markets. Dengue has been part of our coverage since it first became a serious vaccine prospect, and this MarketVIEW edition has been consistently well received by clients precisely because it treats the endemic public-health market as a distinct, deeply modelled opportunity rather than folding it into a generic global forecast. Travel-related dengue vaccination demand is deliberately out of scope here and is covered in full in our companion Travel Vaccines Segment Report (VAMV090).

What the report actually gives a client is a way to price an endemic market in simultaneous transition: an explicit account of Dengvaxia's wind-down and the demand it leaves behind, a country-by-country view of Qdenga's expansion including the unresolved US access question, and an early, considered read on Butantan-DV's rollout economics as the world's first single-dose dengue vaccine - underpinned by value and volume forecasts across 55 endemic markets to 2036, including intra-country roll-out detail for Brazil and India. This edition was published in September 2024. Subject to sufficient client buy-in, a new syndicated edition would be produced to capture the Dengvaxia exit, Qdenga's continued scale-up and the Butantan-DV rollout in full; alternatively, bespoke, ad-hoc analysis is available now on a commissioned basis for clients who need a faster or more tailored answer.

MarketVIEW · VAMV025 · Syndicated refresh or bespoke

License the September 2024 edition - or commission new work

The September 2024 edition of VAMV025 remains available directly from VacZine Analytics. Subject to sufficient client buy-in, we would produce a new syndicated edition covering the Dengvaxia exit, Qdenga's scale-up and the Butantan-DV rollout; alternatively, bespoke, ad-hoc dengue analysis can be commissioned now - a briefing call is included on request.